20th week of 2012 patent applcation highlights part 51 |
Patent application number | Title | Published |
20120122709 | LIBRARIES OF 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY - New compounds are continually sought after for the treatment and prevention of disorders. The invention relates to 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides which can be biologically and pharmacologically traced, in order to be used in the search for, and identification of, new lead compounds that can modulate the functional activity of a biological target. | 2012-05-17 |
20120122710 | LIBRARIES OF N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY - New compounds are continually sought after for the treatment and prevention of disorders. The invention relates to N-substituted-N-phenylethylsulfonamides which can be biologically and pharmacologically traced, in order to be used in the search for, and identification of, new lead compounds that can modulate the functional activity of a biological target. | 2012-05-17 |
20120122711 | SCREENING OF BIOPOLYMERS - Described herein are inventive compositions and methods relating to sampling of biopolymers and, in particular, to fractional sampling of biopolymers. In one aspect, embodiments are generally related to unique biopolymer species where a fraction of each biopolymer species contains a cleavable linker. The biopolymer species may, in some embodiments, be attached to a surface. For example, the biopolymer species may be attached to beads. In some embodiments, a portion of a unique biopolymer species may be sampled by cleaving the cleavable linker. In some cases, the sample may be analyzed to determine the sequence of the biopolymer. | 2012-05-17 |
20120122712 | Methods for Sequencing a Biomolecule by Detecting Relative Positions of Hybridized Probes - A sequencing method is presented in which a biomolecule is hybridized with a specially chosen pool of different probes of known sequence which can be electrically distinguished. The different probe types are tagged such that they can be distinguished from each other in a Hybridization Assisted Nanopore Sequencing (HANS) detection system, and their relative positions on the biomolecule can be determined as the biomolecule passes through a pore or channel. The methods eliminate, resolve, or greatly reduce ambiguities encountered in previous sequencing methods. | 2012-05-17 |
20120122713 | RNA LABELING METHOD - A method of sample analysis is provided. In certain embodiments, the method involves: a) obtaining a fragmented RNA sample comprising fragments of long RNA molecules and short RNA molecules; b) ligating an adaptor to an end of the RNA of the fragmented RNA sample to produce an adaptor-ligated sample; c) hybridizing said adaptor-ligated sample to an array of nucleic acid probes; and d) reading said array to obtain an estimate of the abundance of a long RNA in the RNA sample and an estimate of the abundance a small RNA in the RNA sample. | 2012-05-17 |
20120122714 | SANDWICH ASSAYS IN DROPLETS - The invention generally relates to performing sandwich assays in droplets. In certain embodiments, the invention provides methods for detecting a target analyte that involve forming a compartmentalized portion of fluid including a portion of a sample suspected of containing a target analyte and a sample identifier, a first binding agent having a target identifier, and a second binding agent specific to the target analyte under conditions that produce a complex of the first and second binding agents with the target analyte, separating the complexes, and detecting the complexes, thereby detecting the target analyte. | 2012-05-17 |
20120122715 | ELECTRICAL SENSOR FOR ULTRASENSITIVE NUCLEIC ACID DETECTION - The present invention is direct to a sensor for detecting a nucleic acid molecule comprising an electrode arrangement with two electrodes and nucleic acid probes immobilized at the surface of the electrodes. The present invention also refers to a kit and a method of using the sensor or a sensor array. The present invention is further directed to a process of manufacturing a sensor and sensor array. | 2012-05-17 |
20120122716 | CELL LINE DERIVED FROM THE EPITHELIAL LINING OF THE HUMAN ENDOLYMPHATIC SAC IN THE INNER EAR - In some embodiments, the invention relates to a stable, long-term human ES cell line. In other aspects, the invention relates to methods for establishing a stable long-term ES cell line and methods for screening therapeutic treatments for inner ear diseases, such as Meniere's disease. | 2012-05-17 |
20120122717 | COMPOSITION AND MULTIPLEX ASSAYS FOR MEASURING BIOLOGICAL MEDIATORS OF PHYSIOLOGICAL HEALTH - Multiplex assays are provided including panels of probes for development of multiplex assays capable of simultaneously measuring multiple biologically-relevant proteins using very small quantities of biological samples to rapidly assess the health status of animals, especially companion animals, as well as to formulate nutritional regimens for improving the health status of animals. The probes are provided as are methods for using them to assess the health status of animals, as well as their responses to therapeutic or nutritional interventions therein. | 2012-05-17 |
20120122718 | BRM Expression and Related Diagnostics - The present invention relates to isolated polynucleotides comprising a polymorphism in a promoter region of a BRM gene, and methods and compounds for causing BRM re-expression in cells, such as cancer cells, that have lost BRM expression. The present invention also relates to screening methods for identifying BRM expression-promoting compounds, and to methods of accessing cancer risk through the identification of polymorphisms in the BRM promoter. | 2012-05-17 |
20120122719 | Methods for PCR and HLA typing using unpurified samples - Provided are methods for amplifying a gene or RNA or sets thereof of interest using a tandem PCR process. The primers in the first PCR or set of PCR reactions are locus-specific. The primers in the second PCR or set of PCR reactions are specific for a sub-sequence of the locus-specific primers and completely consumed during the second PCR amplification. For RNA amplification, the first PCR is reverse transcription and the resulting cDNA(s) provide a template for cRNA synthesis, endpoint PCR or real time PCR. Also provided is a tandem PCR method which accepts raw, completely unpurified mouthwash, cheek swabs and ORAGENE™-stabilized saliva as the sample input, the resulting amplicons serving as the substrate for complex, microarray-based genetic testing. Also provided is a method of allelotyping a gene or set thereof by amplifying the gene(s) using tandem PCR on DNA or RNA comprising the sample. | 2012-05-17 |
20120122720 | MEANS AND METHODS FOR RECOGNIZING THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN AN INDIVIDUAL - A method of recognizing the development of an Acute Myocardial Infarction (AMI) process in an individual, wherein the method comprises steps of: profiling specific antibody reactivities or biomarkers associated with AMI susceptibility, the profiling comprises steps of: attaching a set of defined antigens to a substrate; obtaining a biological fluid derived specimen from an individual, the specimen containing a specific antibody repertoire; and binding said antibodies of the biological fluid specimen to the attached antigens thereby forming bound antibody antigen complexes; and analyzing results obtained, wherein the presence of the complexes is indicative of AMI. | 2012-05-17 |
20120122721 | METHOD FOR NUCLEIC ACID DETECTION USING VOLTAGE ENHANCEMENT - Methods are provided for carrying out nucleic acid analysis, including sequence identification, employing voltage and/or controlled electric charge to enhance operation. A device comprises substrates for nucleic acid analysis, a first electrically conductive layer, a first electrically insulative layer of dielectric material on the first conductive layer, a second electrically conductive layer disposed upon the first insulative layer in a pattern to define discrete attachment sites for macromolecules on the first insulative layer, the second conductive layer provided with means for resisting affinity for the macromolecules to impede their attachment to sites on the second conductive layer, and terminals for the first and second conductive layers for applying a voltage pattern between the first and the second conductive layers to control affinity between the macromolecules and the discrete attachment sites. | 2012-05-17 |
20120122722 | Expression of MBNL2 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 2012-05-17 |
20120122723 | METHODS OF DETECTING AUTOANTIBODIES FOR DIAGNOSING AND CHARACTERIZING DISORDERS - Methods for detecting and/or quantitating levels of autoantibodies in subjects are provided. Methods for diagnosing and/or characterizing a disorder associated with autoantibody production are further provided. In some embodiments, the disorder diagnosed and/or characterized can be a cancer or an infertility disorder. | 2012-05-17 |
20120122724 | Agents and Methods Related to Reducing Resistance to Apoptosis-Inducing Death Receptor Agonists - Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | 2012-05-17 |
20120122725 | Method of determining risk of a neuropsychiatric disorder - A method of assessing risk of ADHD in a human subject is provided. The method comprises the step of identifying in a nucleic acid-containing sample obtained from the human subject copy number variations associated with one or more genes selected from the group consisting of DCLK1, DCLK2, SORCS3, SORCS1, 16p11.2, ASTN2, MACROD2, CHCHD, CPLX2, ZBBX, PTPRN2 and TRIM32 wherein a determination of copy number variations associated with one or more of said genes is indicative of a risk of ADHD in the human subject. | 2012-05-17 |
20120122726 | MARKERS FOR ENDOMETRIAL CANCER - The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals. | 2012-05-17 |
20120122727 | IN VITRO METHOD FOR PREDICTING WHETHER A COMPOUND IS GENOTOXIC IN VIVO - The invention is in the field of genomics and it provides an in vitro method for predicting whether a compound is genotoxic in vivo. It provides a method that employs the analysis of expression profiles of primary mouse hepatocytes as an in vitro system to discriminate false GTX compounds from true GTX carcinogens. It was found that differential expression of a number of genes could reliably predict whether a compound was a true genotoxic compound. | 2012-05-17 |
20120122728 | Method Of Screening Drugs For Reversal Of Amyloid Beta Neurotoxicity - A method of screening a compound for effectiveness in treating amyloid beta neurotoxicity comprises culturing mammalian neurons in serum-free defined medium until the neurons are electrically functional, exposing the electrically stable neurons to amyloid beta, monitoring the exposed neurons for impairment of electrical functionality, and treating the exposed neurons with the candidate drug while monitoring their electrical activity for reversal of impairment. The invention also includes a method of identifying a mammalian neuron having a biological marker conferring predisposition to development of Alzheimer's disease, the method comprising culturing the mammalian neuron in serum-free medium until the neuron is electrically functional, exposing the electrically stable neuron to amyloid beta while monitoring for impairment of electrical functionality as an indicator of presence of said biological marker, and verifying presence of the biological marker by treating the impaired neuron with an anti-amyloidogenic compound while monitoring for return of neuron functionality. | 2012-05-17 |
20120122729 | Methods and Tests for Screening Bacterial Biofilms - In a first aspect, the present invention relates to a method for screening bacteria on their susceptibility against candidate compounds. In a further aspect, the present invention relates to a method for screening the antibiotic efficacy of candidate compounds suppose to have an antibiotic activity on bacteria. Moreover, the present invention relates to a method for forming a bacterial biofilm on a support, a system allowing in vitro and in vivo evaluation of biofilms formed by bacteria as well as methods for the stratification of the treatment regimen against bacterial infections. | 2012-05-17 |
20120122730 | Methods for Quantitative Analyses of Kinase Inhibitor Selectivity Using Small Size Panels - Methods for analyses of kinase inhibitor specificity and promiscuity using small subsets of kinases including a method comprising providing a set of kinases, ranking the kinases based upon their ability to overcome biases, utilizing a correlation-based feature selection algorithm to select a kinase inferential bases, and screening a kinase inhibitor against the kinase inferential bases. | 2012-05-17 |
20120122731 | Screening molecular libraries using microfluidic devices - Screening in a microfluidic device is mediated by a magnetic field that in some manner displaces or otherwise activates the entities of interest. Entities of interest can be identified and/or separated from one or more other components provided to the microfluidic device. Microfluidic devices may have mechanisms that apply a defined magnetic field to a region of the microfluidic device where library members pass through sequentially and/or in parallel. | 2012-05-17 |
20120122732 | Magnetic nanoparticles, magnetic detector arrays, and methods for their use in detecting biological molecules - Magnetic nanoparticles and methods for their use in detecting biological molecules are disclosed. The magnetic nanoparticles can be attached to nucleic acid molecules, which are then captured by a complementary sequence attached to a detector, such as a spin valve detector or a magnetic tunnel junction detector. The detection of the bound magnetic nanoparticle can be achieved with high specificity and sensitivity. | 2012-05-17 |
20120122733 | COMPOSITION, DEVICE AND ASSOCIATED METHOD - The composition includes a first probe and a first initiator bonded to the first probe. The composition further includes a second probe and a second initiator bonded to the second probe. The first probe and the second probe are capable of binding to a single analyte. An associated kit, device, and method are provided. | 2012-05-17 |
20120122734 | COMPOSITION, DEVICE AND ASSOCIATED METHOD - A composition includes a first probe and a first initiator bonded to the first probe. The first probe is capable of binding to an analyte and the first initiator is capable of initiating a controlled polymerization reaction. An associated kit, device, and method are provided. | 2012-05-17 |
20120122735 | COMPOSITION, DEVICE AND ASSOCIATED METHOD - A composition includes a first probe, a first initiator component bonded to the first probe, a second probe, and a second initiator component bonded to the second probe. The first probe and the second probe are capable of binding to a single analyte, and the first initiator component and the second initiator component are capable of forming an initiator when present in proximity to each other and when the first probe and the second probe are bonded to the analyte. An associated kit, device, and method are provided. | 2012-05-17 |
20120122736 | SENSORS INCORPORATING ANTIBODIES AND METHODS OF MAKING AND USING THE SAME - A sensor comprising an electronic circuit electrically coupled to a type III-V semiconductor material, for example indium arsenide (InAs) and an antibody contacting the type III-V semiconductor material. The sensor produces measurable N changes in the electrical properties of the semiconductor upon antibody-antigen binding events. Electrical properties measurable by the electronic device may include resistivity, capacitance, impedance, and inductance. A method of detecting an antigen using sensors of the invention. A method of detecting a reaction of an analyte to a stimulus using sensors of the invention. Sensor arrays comprising multiple sensors of the invention. | 2012-05-17 |
20120122737 | METHODS FOR SELECTING AND AMPLIFYING POLYNUCLEOTIDES - The invention provides methods for controlling the density of different molecular species on the surface of a solid support. A first mixture of different molecular species is attached to a solid support under conditions to attach each species at a desired density, thereby producing a derivatized support having attached capture molecules. The derivatized support is treated with a second mixture of different molecular species, wherein different molecular species in the second mixture bind specifically to the different capture molecules attached to the solid support. One or more of the capture molecules can be reversibly modified such that the capture molecules have a different activity before and after the second mixture of molecular species are attached. In particular embodiments, the different molecular species are nucleic acids that are reversibly modified to have different activity in an amplification reaction. | 2012-05-17 |
20120122738 | METHOD FOR PREPARING A GELLING AND VISCOSIFYING AGENT FOR DRILLING MUD AND THE PRODUCT THEREOF - A method for preparing lignin graft copolymer comprising: reacting lignocellulosic materials with an acrylic compound by bulk condensation under nitrogen atmosphere in the presence of a non-oxidizing strong organic acid as catalyst; separating the reaction mixture to obtain a solid phase mainly containing lignocellulosic materials and a liquid phase containing lignin graft copolymer and unreacted acrylic compound; and removing solvent from the liquid phase to obtain the lignin graft copolymer. | 2012-05-17 |
20120122739 | VISCOSIFYING POLYMERS AND METHODS OF USE - Fluids for use within a wellbore are provided, comprising amorphous polyalphaolefins and/or amorphous polyisobutylene in an oil-based hydrocarbon solvent. Novel properties of such fluids are described, and the fluids may be used, for example, during drilling or fracturing operations. | 2012-05-17 |
20120122740 | Heavy oil recovery process using extremophile anaerobic indigenous microorganisms - A process for increasing recovery of heavy oil with an API gravity equal to or greater than 10, contained in carbonate and/or sandstone porous media using extremophile (thermophilic, halotolerant and barotolerant) anaerobic indigenous microorganisms. The process involves nutrient injection to stimulate activity of extremophile anaerobic indigenous microorganisms at the well bottom, promoting the production of metabolites which improve oil mobility and increase oil recovery. Stimulation of extremophile anaerobic indigenous microorganisms and their metabolite production is conducted under anaerobic conditions at temperatures of 45 to 90° C., NaCl concentrations of 5,000 to 40,000 mg/L and pressures of 0.795 to 169 Kg/cm | 2012-05-17 |
20120122741 | Scale Inhibiting Particulates - Scale inhibiting particulates formed from a mixture of fly ash and a phosphonic acid curing agent; wherein the fly ash is cured into a solid material by the contact with the phosphonic acid curing agent. The mixture may also contain a multivalent ion and the particulates may be coated with a coating material in an amount from about 0.1% to about 40% coating material by weight of the scale inhibiting particulate to delay the release of the scale inhibitor. | 2012-05-17 |
20120122742 | LUBRICANT STICK FORMULATIONS - A solid lubricant formulation useful for lubricating the flanges of locomotive wheels, railcar wheels, rail tracks and in applications where it is desirable to reduce friction when metal contacts metal. The solid lubricant formulation including at least one non-polylactic acid-based polymeric carrier, at least one polylactic acid-based polymer, and at least one lubricant powder. | 2012-05-17 |
20120122743 | LUBRICANT AND SYNERGISTIC ADDITIVE FORMULATION - A friction modifying lubricant additive is provided comprising a base oil, colloidal nanocarbon particles, and a fluorine containing oligomeric dispersant. The fluorine containing oligomeric dispersant includes an anchoring group, a lipophilic hydrocarbon group, and a fluorinated oleophobic group. Further, a friction modifying lubricant additive is provided comprising a base oil, colloidal nanocarbon particles, a fluorine containing oligomeric dispersant, and at least one component selected from the group consisting of an antifriction component, an antiwear component, and an extreme pressure component. In another aspect, a method of manufacturing a lubricant additive is provided, the method comprising the step of mixing together a fluorine containing oligomeric dispersant, a dispersion of colloidal nanocarbon particles in a first base oil, and a second base oil. | 2012-05-17 |
20120122744 | Imides and Bis-Imides as Friction Modifiers in Lubricants - A composition is provided for use as a friction modifier for an automatic transmission, which comprises a condensation product of a hydroxypolycarbox-ylic acid, such as 2,3-di-hydroxybutanedioic acid or 2-hydroxybutanedioic acid, with an N,N-di(hydrocarbyl)alkylenediamine, where each hydrocarbyl group contains 1 to 22 carbon atoms, provided that the total number of carbon atoms in the two hydrocarbyl groups is at least about 9, and the alkylene group contains 2 to 4 carbon atoms. | 2012-05-17 |
20120122745 | KETAL COMPOUNDS AND USES THEREOF - Various esterified alkyl ketal ester or hydroxyalkyl ketal ester products are useful as components of organic polymer compositions. The ketal esters are produced in certain transesterifications between alkyl ketal esters and/or hydroxyalkyl ketal esters and polyols, aminoalcohols, polyamines and/or polycarboxylic acids. The products are excellent plasticizers for a variety of organic polymers, notable poly(vinyl chloride) plastisols. The products are also very good lubricants for many lubrication applications. | 2012-05-17 |
20120122746 | Compositions - A surfactant composition comprising: | 2012-05-17 |
20120122747 | POLYMER-CONTAINING CLEANING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF - The present invention provides detergent compositions, essentially free of peroxygen or chlorine bleach compounds, containing one or more surfactants, one or more builders, one or more enzymes and one or more low MW (e.g., 0.8-25 kDa) polyethyleneimine (PEI) polymers or salts thereof, and methods of producing such compositions. The compositions of the invention provide certain benefits in cleaning of textiles (particularly fabrics including clothing), hard surfaces and dishware and utensils, including enhanced removal of certain difficult-to-remove stains such as chocolate pudding and grass, as well as of polyphenolic stains such as cherry juice, blueberry juice, red wine, tea and coffee. The invention also provides methods of using these compositions in laundry, hard surface cleaning and dishwashing applications. | 2012-05-17 |
20120122748 | DETERGENT FORMULATIONS FOR MACHINE DISHWASHING COMPRISING HYDROPHILICALLY MODIFIED POLYCARBOXYLATES - A mixed powder or mixed granule for use in detergent formulations for machine dishwashing contains the following components: a) from 10 to 95% by weight of a copolymer of al) from 50 to 93 mol % of acrylic acid and/or of a water-soluble salt of acrylic acid, a2) from 5 to 30 mol % of methacrylic acid and/or of a water-soluble salt of methacrylic acid, and a3) from 2 to 20 mol % of at least one nonionic monomer, wherein monomers a1) to a3) are copolymerized in a random or block manner, b) from 5 to 80% by weight of a complexing agent selected from the group consisting of a glycine-N,N-diacetic acid derivative and glutamic acid N,N-diacetic acid and salts thereof, c) from 0 to 20% by weight of a polyethylene glycol, of a nonionic surfactant or of a mixture thereof. | 2012-05-17 |
20120122749 | METAL LOSS INHIBITOR FORMULATIONS AND PROCESSES - In one embodiment, a metal loss inhibitor concentrate is provided which contains water, (A) a component of dissolved organic compounds and polymers that contain at least two hydroxy moieties per molecule and an average of at least 0.4 hydroxy moieties per carbon atom; (B) a thiourea component; and (C) a dissolved component containing aryl and quaternary ammonium moieties; and, optionally: (D) a wetting agent, such as a component of an ethoxylate of an alcohol. Such solutions form useful inhibitor concentrates when combined with aqueous chelating cleaning solutions, wherein such solutions, when contacted with a metal surface, are effective in removing scale, smut and other deposits from the metal surface but exhibit a reduced tendency to attack or unduly etch the metal itself, or to inhibit the subsequent desired oxidation and dissolution of metallic copper deposits. | 2012-05-17 |
20120122750 | DETERGENT COMPOSITION COMPRISING BLUING AGENT AND RAPIDLY WATER-SOLUBLE BRIGHTENER - A solid laundry detergent composition having: (a) detersive surfactant; (b) bluing agent; (c) C.I. fluorescent brightener 260; and (d) optionally, one or more additional laundry detergent ingredients. | 2012-05-17 |
20120122751 | DETERGENT COMPOSITION COMPRISING BLUING AGENT AND CLAY SOIL REMOVAL / ANTI-REDEPOSITION AGENT - A laundry detergent composition having: (a) detersive surfactant; (b) bluing agent, and (c) a clay and soil removal/anti-redeposition agent; and (d) optionally, one or more additional laundry detergent ingredients. | 2012-05-17 |
20120122752 | DETERGENT COMPOSITIONS - The present invention relates to new compositions comprising compounds, which are molecular combinations of a phthalocyanine and a mono-azo dyestuff linked via specific linking groups. Further aspects are an improved shading process for textile materials and also use of these shading compositions for shading textiles. | 2012-05-17 |
20120122753 | LIQUID WASHING OR CLEANING AGENT COMPRISING ANTI-GRAYING POLYSACCHARIDE - The present invention relates to a stable liquid washing or liquid cleaning agent comprising an anti-graying polysaccharide. The invention further relates to the use of the liquid washing or liquid cleaning agent and to a method for the production thereof. | 2012-05-17 |
20120122754 | Alpha-Amylase Variants - The invention relates to a variant of a parent Termamyl-like alpha-amylase, which variant exhibits altered properties, in particular reduced capability of cleaving a substrate close to the branching point, and improved substrate specificity and/or improved specific activity relative to the parent alpha-amylase. | 2012-05-17 |
20120122755 | POLYGLYCERYL COMPOUNDS AND COMPOSITIONS - Provided are compositions comprising one or more compounds having a structure comprising a node structure with from four to twelve carbon atoms, one or more (poly)glyceryl groups, and one or more hydrophobic moieties, wherein each of the one or more (poly)glyceryl groups is linked to the node structure by a first primary linking group, the one or more hydrophobic moieties are each independently linked either to the node structure by a primary linking group or to one of the (poly)glyceryl groups by a secondary linking group, and wherein the polyglyceryl thickener has an average degree of glyceryl polymerization of from greater than 3 to less than about 11 and an average number of hydrophobic groups per primary linking group of about 0.35 or greater. Also provided are polyglyceryl compounds, compositions comprising water, a surfactant, and a polyglyceryl thickener, as well as, methods of making polyglyceryl compounds and compositions of the present invention. | 2012-05-17 |
20120122756 | Hard surface cleaning composition for personal contact areas - A hard surface cleaning solution having improved cleaning and descaling properties. In an embodiment, the cleaning solution comprises an organic acid, a surfactant, a solvent and a diluent. The first organic acid is a carboxylic acid, preferably lactic acid, while the surfactant is selected from the group consisting amine oxides, and the solvent is an alkoxylated alcohol, preferably selected from the propylene glycol ether class of compounds. The cleaning solutions may also include other components such as colorants, fragrance enhancers, corrosion inhibitors, nonionic surfactants or other additives. | 2012-05-17 |
20120122757 | Hard surface cleaning composition - A hard surface cleaning solution having improved cleaning and descaling properties. The cleaning solution includes the following components: a first organic acid, a second organic acid, a surfactant, a solvent and a diluent. The first organic acid is a carboxylic acid, preferably lactic acid, while the second organic acid is also a carboxylic acid, preferably gluconic acid. The surfactant is selected from the group consisting of amine oxides, preferably lauramine oxide. The solvent may be an alkoxylated alcohol, preferably selected from the propylene glycol ether class of compounds. | 2012-05-17 |
20120122758 | POLYGLYCERYL COMPOUNDS AND COMPOSITIONS - Provided are compositions comprising one or more compounds having a structure comprising a node structure with from four to twelve carbon atoms, one or more (poly)glyceryl groups, and one or more hydrophobic moieties, wherein each of the one or more (poly)glyceryl groups is linked to the node structure by a first primary linking group, the one or more hydrophobic moieties are each independently linked either to the node structure by a primary linking group or to one of the (poly)glyceryl groups by a secondary linking group, and wherein the polyglyceryl thickener has an average degree of glyceryl polymerization of from greater than 3 to less than about 11 and an average number of hydrophobic groups per primary linking group of about 0.35 or greater. Also provided are polyglyceryl compounds, compositions comprising water, a surfactant, and a polyglyceryl thickener, as well as, methods of making polyglyceryl compounds and compositions of the present invention. | 2012-05-17 |
20120122759 | METHODS FOR REMOVING A CONTAMINANT USING INDIGENOUS PROTEIN DISPLACEMENT ION EXCHANGE MEMBRANE CHROMATOGRAPHY - Methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant are described, which methods comprise the sequential steps of: (a) passing the composition through an ion exchange membrane, where the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pI of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and the at least one contaminant, and (b) recovering the purified polypeptide from the effluent. | 2012-05-17 |
20120122760 | NOVEL LIPIDS FOR TRANSFECTION OF NUCLEIC ACIDS - Cationic lipid compositions are provided that are useful for efficient delivery of macromolecules, such as nucleic acids, into a wide variety of eukaryotic cell types. Methods for using the compositions also are provided. | 2012-05-17 |
20120122761 | METHODS FOR DETECTING A POLYMORPHISM IN THE NFKB1 GENE PROMOTER - The present invention discloses a functional relationship between a recognized disease condition and a polymorphism in the nucleotide factor kappa B promoter (NFKB1). This relationship provides a platform for methods of altering promoter activity and for determining similar relationships between specific pathologies and identified polymorphisms. A statistically significant risk of developing ulcerative colitis was shown to be correlated with the presence of an ATTG insertion/deletion in the NFKB1 promoter and is likely to apply also to a variety of other inflammatory diseases. | 2012-05-17 |
20120122762 | 186 Human Secreted Proteins - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 2012-05-17 |
20120122763 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS - The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors. | 2012-05-17 |
20120122764 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP - The present invention provides a compound of formula I; | 2012-05-17 |
20120122765 | COMPOUNDS AND RELATED METHODS FOR MANIPULATING PARP-1-DEPENDENT CELL DEATH - Apoptosis inducing factor (“AIF”) contains a PAR-binding motif (“PBM”) that binds to Poly(ADP-ribose) (“PAR”). Binding of PAR to AIF via the PBM is required for AIF release from the mitochondria to occur, and that this PAR-related release is a key step in the programmed cell death process known as parthanatos, both in vitro and in vivo. Preventing or disrupting this release can inhibit parthanatos and thus be the basis for treatments for patients suffering from diseases or medical conditions during which parthanatos commonly occurs, including Parkinson's disease or diabetes, or patients who have had and are recovering from heart attack, stroke and other ischemia reperfusion-related injuries. Alternatively, agents could be identified that enhance the release of AIF, thereby promoting parthanatos and serving as potential anti-tumor chemotherapeutic agents. | 2012-05-17 |
20120122766 | Novel Polypeptide Having Angiogenesis-Inducing Activity And Antibacterial Activity, And Use Thereof For Medical Purposes - Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like. | 2012-05-17 |
20120122767 | LACTOFERRIN-BASED BIOMATERIALS FOR TISSUE REGENERATION AND DRUG DELIVERY - The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As described herein, cross-linked lactoferrin biomatrix retains the bioactivities of the lactoferrin molecule. The biomatrix composition can act as a matrix for cell adhesion and growth and is particularly useful in musculoskeletal tissue regeneration. The biomatrix compositions can be pre-formed or injectable and can act as a cell, drug or protein delivery vehicle. | 2012-05-17 |
20120122768 | ALGINATE OLIGOMERS FOR USE IN OVERCOMING MULTIDRUG RESISTANCE IN BACTERIA - The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes. | 2012-05-17 |
20120122769 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS - Antibacterial antisense compounds and methods of their use in treating a | 2012-05-17 |
20120122770 | Cell Cycle Arrest and Apoptosis - The HIV-1 accessory gene vpr encodes a conserved 96-amino acid protein that is necessary and sufficient for the HIV-1-induced block of cellular proliferation and induction of apoptosis. Expression of vpr in CD4.sup.+ lymphocytes results in G2 arrest, followed by apoptosis. ATR, as a cellular factor that mediates Vpr-induced cell cycle arrest, is required for activation of the Breast Cancer-Associated Protein-1 (BRCA1). In addition, the Growth Arrest and DNA Damage protein (GADD45) is upregulated by Vpr in an ATR-dependent manner. Posttranscriptional silencing of either ATR or GADD45 leads to nearly complete suppression of the pro-apoptotic and/or cell cycle arrest effect of Vpr. | 2012-05-17 |
20120122771 | STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN - The present invention relates generally to structural studies of the insulin binding site of the insulin receptor (IR) and the insulin-like growth factor 1 receptor (IGF-1R). More particularly, the present invention relates to the crystal structure of the low affinity insulin binding site of the IR ectodomain comprising the C-terminal region of the IR α-chain, as well as the corresponding region of IGF-1R, and to methods of using the crystal and related structural information to screen for and design compounds that interact with or modulate the function of IR and/or IGF-1R. | 2012-05-17 |
20120122772 | Agent for Suppressing Elevation of Blood GIP Concentration - An agent for suppressing elevation of blood GIP concentration and an agent for preventing or improving obesity, each of which contains a polyglutamic acid as an active ingredient. | 2012-05-17 |
20120122773 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE - The present invention provides a compound of formula (I): | 2012-05-17 |
20120122774 | LONG-ACTING FORMULATIONS OF INSULINS - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 2012-05-17 |
20120122775 | Use of Ultrarapid Acting Insulin - Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. | 2012-05-17 |
20120122776 | DPP-IV INHIBITORS FOR TREATMENT OF DIABETES IN PEDIATRIC PATIENTS - The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in paediatric patients. | 2012-05-17 |
20120122777 | DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP - The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor. | 2012-05-17 |
20120122778 | Modified TGF-beta superfamily protein - The invention provides modified TGF-β family proteins having altered biological or biochemical properties, and methods for making them. Specific modified protein constructs include TGF-β family member proteins that have N-terminal truncations, “latent” proteins, fusion proteins and heterodimers. | 2012-05-17 |
20120122779 | Method for site-specific polyvalent display on polymers - The present invention relates to novel complex peptidomimetic products comprising multiple homogeneous or heterogeneous pendant groups that are site-specifically positioned along a linear oligomer or polymer scaffold and methods of making thereof. More specifically, the invention relates to N-substituted glycine peptoid oligomers or peptoids and their use as substrates for azide-alkyne [3+2]-cycloaddition conjugation reactions and subsequent additional rounds of oligomerization and cycloaddition. The methods of the invention may also be used to generate peptoid-peptide hybrid or peptide products comprising multiple homogeneous or heterogeneous pendant groups, which are positioned precisely along the linear oligomer or polymer scaffold. | 2012-05-17 |
20120122780 | Compounds, Compositions and Methods for Modulating Uric Acid Levels - Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 2012-05-17 |
20120122781 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS - Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed. | 2012-05-17 |
20120122782 | COMPLEXATION OF METAL IONS WITH POLYPEPTIDES - Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of individual polypeptide molecules is reduced when aqueous media is introduced to such formulations, serving to stabilize the polypeptide. | 2012-05-17 |
20120122783 | GLUCAGON ANTAGONISTS - Glucagon antagonists are provided which comprise amino acid substitutions and/or chemical modifications to glucagon sequence. In one embodiment, the glucagon antagonists comprise a native glucagon peptide that has been modified by the deletion of the first two to five amino acid residues from the N-terminus and (i) an amino acid substitution at position 9 (according to the numbering of native glucagon) or (ii) substitution of the Phe at position 6 (according to the numbering of native glucagon) with phenyl lactic acid (PLA). In another embodiment, the glucagon antagonists comprise the structure A-B-C as described herein, wherein A is PLA, an oxy derivative thereof, or a peptide of 2-6 amino acids in which two consecutive amino acids of the peptide are linked via an ester or ether bond. | 2012-05-17 |
20120122784 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF - The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments. | 2012-05-17 |
20120122785 | COMBINATION OF A LEUCINE SOURCE AND AN OMEGA- 3 UNSATURATED FATTY ACID SOURCE FOR USE IN THE TREATMENT OF HYPERCALCAEMIA - The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis. | 2012-05-17 |
20120122786 | Use of Polypeptide Micromolecule MLIF in Preparing Medicine for Preventing and Treating Myocardial Ischemia - Use of polypeptide micromolecule MLIF in preparing medicine for preventing and treating myocardial ischmia, where amino acid sequence of the polypeptide micromolecule MLIF is Met-Gln-Cys-Asn-Ser (SEQ ID NO:1). | 2012-05-17 |
20120122787 | METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES - The present invention is directed to, inter alia, methods of treating or ameliorating an effect of a polycystic disease. This method include administering to a patient in need thereof an amount of a modulator of a histone deacetylase (HDAC) path-way, which is sufficient to treat or ameliorate an effect of a polycystic disease, particularly a polycystic kidney disease. | 2012-05-17 |
20120122788 | E-POLYLYSINE CONJUGATES AND THE USE THEREOF - The present invention relates to ε-polylysine conjugates, in particular conjugates of ε-polylysine with compounds carrying carboxyl groups, and to the preparation and use thereof for targeting of the kidney. | 2012-05-17 |
20120122789 | Methods of Reducing Myocardial Injury Following Myocardial Infarction - The present invention discloses methods of reducing injury resulting from cardiovascular disease, such as myocardial infarction, and/or promoting myocardial repair. The methods include administering an ephrin and pharmaceutical compositions including ephrins to a subject. Kits useful for accomplishing the same are also provided. | 2012-05-17 |
20120122790 | METHODS FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA AND RELATED DISORDERS - The disclosure provides methods of treating X-linked hypophosphatemia, related bone demineralization and renal phosphate wasting disorders in a mammalian subject. The methods comprise administering to the subject an effective amount of a polyarginine peptide | 2012-05-17 |
20120122791 | SUBSTRATE FOR CARTILAGE CULTIVATION USING ARTIFICIAL COLLAGEN, AND METHOD FOR CARTILAGE REGENERATION TREATMENT USING THE SUBSTRATE - Provided are a substrate for cartilage cultivation, which exhibits high safety and has a growth promoting effect on cartilage cells, and a method for cartilage regeneration treatment. The substrate for cartilage cultivation containing artificial collagen, in particular, an artificial collagen aqueous solution has a growth promoting effect on cartilage cells. A cartilage regeneration effect is obtained by the intraarticular injection of the substrate in and around a cartilage defect site. | 2012-05-17 |
20120122792 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS - S-t-butyl protected cysteine di-peptide analogs and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS). | 2012-05-17 |
20120122793 | S-Protected Cysteine Analogs and Related Compounds - S-protected cysteine analogs and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS). | 2012-05-17 |
20120122794 | Compound And Method For Treatment Of Alzheimer's Disease - An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man. | 2012-05-17 |
20120122795 | ACCELERATED EXTENSION OF AXONS - The present disclosure relates to methods and compositions for promoting the extension of a neural cell by increasing the expression of activity of cofilin in the cell. The increase can be local to the end of the neural cell in need of extension and the neural cell can be a cell in an individual. By extending the neural cell to reach its synaptic target, the methods and compositions of the present disclosure can also be used for treating neurological diseases characterized by damaged or degenerated neurons. | 2012-05-17 |
20120122796 | CELL PERMEABLE P53 RECOMBINANT PROTEIN, POLYNUCLEOTIDE ENCODING THE SAME, AND ANTI-CANCER COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT - Disclosed are a cell-permeable p53 recombinant protein in which a macromolecule transduction domain (MTD) is fused to the tumor suppressor p53, a polynucleotide encoding the same, a recombinant expression vector for producing the same, and a pharmaceutical composition of the treatment of cancer, comprising the same. Having high cell permeability, the p53 recombinant protein is effectively transduced into cells so that the tumor suppressor p53 can be translocated into cell nuclei. Within nuclei, p53 inhibits the formation of cyclin-CDK complexes to halt the cell cycle, thus suppressing excessive cell proliferation and inducing apoptosis of tumor cells. Therefore, the p53 recombinant protein can be useful as an anticancer agent in the treatment of various cancers. | 2012-05-17 |
20120122797 | PEPTIDIC COMPOUND AND USE OF SAME - An object of the present invention is to provide a novel compound having an antitumor/anticancer effect. Specifically, the present invention provides a compound represented by Formula (I), a derivative thereof or a salt of the same. In Formula (I), R | 2012-05-17 |
20120122798 | TREATMENT OF OVARIAN CANCER USING AN ANTICANCER AGENT CONJUGATED TO AN ANGIOPEP-2 ANALOG - Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an ammo acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2. | 2012-05-17 |
20120122799 | CYCLIC PEPTIDE ANTITUMOR AGENTS - Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells. | 2012-05-17 |
20120122800 | Long-Acting DNA Dendrimers and Methods Thereof - This invention provides a unique composition which includes a DNA dendrimer combined with siRNA molecule. Further, methods of preparing a composition which includes a DNA dendrimer combined with a siRNA molecule, methods of protecting a DNA dendrimer siRNA complex against degradation in body fluids, methods of protecting a DNA dendrimer against degradation in bodily fluids, and methods of delivering a DNA dendrimer into bodily fluids are provided. | 2012-05-17 |
20120122801 | Mannose-6-phosphate receptor mediated gene transfer into muscle cells - The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes ex on skipping and induces or restores the synthesis of dystrophin or variants thereof. | 2012-05-17 |
20120122802 | ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS - Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients. | 2012-05-17 |
20120122803 | ALPHA-CONOTOXIN MII ANALOGS - The invention relates to novel conopeptides and/or novel uses of conopeptides. The conopeptides of the invention are analogs of α-Conotoxin MII that are selective for α6-containing nAChRs as described herein. | 2012-05-17 |
20120122804 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS - The present invention relates to quinobenzoxazines analogs having the general formula: | 2012-05-17 |
20120122805 | PESTICIDAL COMPOSITIONS - The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed. | 2012-05-17 |
20120122806 | METHOD OF LOWERING GLYCEMIC INDEX OF FOODS - A method of delaying digestion by an animal or a human of carbohydrates in food, comprising administering an effective amount of one or more flavonoids to the animal or human in conjunction with the food, wherein the flavonoids are selected from luteolin, apigenin, tricin and their pharmaceutically acceptable analogues and derivatives. | 2012-05-17 |
20120122807 | Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy - A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin. | 2012-05-17 |
20120122808 | MACROLIDE SYNTHESIS PROCESS AND SOLID-STATE FORMS - Described are methods for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, among other uses, may be used to make macrolides. Also described are solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms. | 2012-05-17 |